Merck & Company Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Operating-Expenses" stands at 26.91 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 06/30/2023.
Merck & Company Inc's third quarter result of 6.60 Billion USD for the item "Operating Expenses" represents a decrease of -1.51 percent compared to it's second quarter result.
Also, Merck & Company Inc's third quarter result of 6.60 Billion USD for the item "Operating Expenses" represents a decrease of -23.24 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Merck & Company Inc's third quarter result of 26.91 Billion USD for the item "Operating Expenses" represents a decrease of -6.91 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -20.23 percent compared to the value the year prior.
The 1 year change in percent is -20.23.
The 3 year change in percent is 16.89.
The 5 year change in percent is 36.07.
The 10 year change in percent is 51.10.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Operating Expenses | 905,699,262,464.00 |
![]() | Johnson & Johnson - Operating Expenses | 486,508,953,600.00 |
![]() | AbbVie Inc - Operating Expenses | 399,570,305,024.00 |
![]() | Roche Holding AG - Operating Expenses | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Operating Expenses | 280,205,508,085.11 |